Pharmacoeconomic Considerations in Treating Iron Overload in Patients with β-Thalassaemia, Sickle Cell Disease and Myelodysplastic Syndromes in the US: A Literature Review

Author： Zhang Bin  

Publisher： Adis International

ISSN： 1170-7690

Source： PharmacoEconomics, Vol.29, Iss.6, 2011-06, pp. : 461-474

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Pharmacoeconomic considerations of treating patients with advanced Parkinson's disease

By Reese Jens P   Dams Judith   Winter Yaroslav   Balzer-Geldsetzer Monika   Oertel Wolfgang H   Dodel Richard  

Expert Opinion on Pharmacotherapy, Vol. 13, Iss. 7, 2012-05 ,pp. : 939-958

Informa Healthcare

Access to resources Recommend Favorite

Red Cell Indices and Functions Differentiating Patients with the β-Thalassaemia Trait from those with Iron Deficiency Anaemia

By Okan V   Cigiloglu A   Cifci S   Yilmaz M   Pehlivan M  

The Journal of International Medical Research, Vol. 37, Iss. 1, 2009-01 ,pp. : 25-30

Field House Publishing

Access to resources Recommend Favorite

Pharmacokinetics of Deferiprone in Patients with β-Thalassaemia: Impact of Splenectomy and Iron Status

By >  

Clinical Pharmacokinetics, Vol. 50, Iss. 1, 2011-01 ,pp. : 41-50

Adis International

Access to resources Recommend Favorite

Use chelation therapy to reduce iron overload and improve survival in patients with myelodysplastic syndromes

By  

Drugs & Therapy Perspectives, Vol. 27, Iss. 9, 2011-09 ,pp. : 14-17

Adis International

Access to resources Recommend Favorite

Pharmacoeconomic Considerations in Treating Patients With Acute Leukaemia

By Jønsson V.  

PharmacoEconomics, Vol. 15, Iss. 2, 1999-02 ,pp. : 167-178

Adis International

Access to resources Recommend Favorite